CN112715938A - Composition for inhibiting prostatic hyperplasia - Google Patents
Composition for inhibiting prostatic hyperplasia Download PDFInfo
- Publication number
- CN112715938A CN112715938A CN202011599001.4A CN202011599001A CN112715938A CN 112715938 A CN112715938 A CN 112715938A CN 202011599001 A CN202011599001 A CN 202011599001A CN 112715938 A CN112715938 A CN 112715938A
- Authority
- CN
- China
- Prior art keywords
- prostatic hyperplasia
- inhibiting
- composition
- parts
- turmeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract description 88
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title claims abstract description 82
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 229940075999 phytosterol ester Drugs 0.000 claims abstract description 37
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 30
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 30
- 235000013976 turmeric Nutrition 0.000 claims abstract description 30
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 244000163122 Curcuma domestica Species 0.000 claims description 34
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 17
- 235000014375 Curcuma Nutrition 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 241000407170 Curcuma Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 235000013305 food Nutrition 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 244000008991 Curcuma longa Species 0.000 abstract 3
- 230000009044 synergistic interaction Effects 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 24
- 239000000047 product Substances 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 14
- 210000002307 prostate Anatomy 0.000 description 10
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 9
- 229960003473 androstanolone Drugs 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 210000002570 interstitial cell Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 206010020718 hyperplasia Diseases 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 5
- 102000009515 Arachidonate 15-Lipoxygenase Human genes 0.000 description 4
- 108010048907 Arachidonate 15-lipoxygenase Proteins 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 235000012754 curcumin Nutrition 0.000 description 4
- 229940109262 curcumin Drugs 0.000 description 4
- 239000004148 curcumin Substances 0.000 description 4
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- -1 endocrine Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 206010071119 Hormone-dependent prostate cancer Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000025844 Prostatic disease Diseases 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000000547 effect on apoptosis Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003784 tall oil Substances 0.000 description 1
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940052016 turmeric extract Drugs 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
- 239000008513 turmeric extract Substances 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition for inhibiting prostatic hyperplasia, which belongs to the field of medical health-care food and consists of the following components: turmeric and phytosterol esters. The turmeric and the phytosterol ester are compounded, and the synergistic interaction between the turmeric and the phytosterol ester can effectively inhibit the hyperplasia of prostate. In addition, the composition for inhibiting the prostatic hyperplasia has high safety and no toxic or side effect. The invention also provides a preparation method of the composition for inhibiting the prostatic hyperplasia, and the preparation method has simple preparation process and can be used for industrial mass production. The invention also provides application of the composition for inhibiting the prostatic hyperplasia in preparation of medical and health-care food.
Description
Technical Field
The invention relates to the field of medical health-care food, in particular to a composition for inhibiting prostatic hyperplasia.
Background
Benign prostatic hyperplasia is a common middle-aged and old-aged male disease, is manifested by symptoms of frequent micturition, urgent micturition, unsmooth urination, increased nocturia, urinary retention and the like, may cause complications such as urinary tract infection, vesical calculus and the like, and even may cause renal function injury. The pathogenesis of prostatic hyperplasia is a very complex pathological process involving a plurality of factors, such as hormones, endocrine, growth factors, inflammatory factors, etc., and the pathogenesis of prostatic hyperplasia can be the result of the single dominant action of one of the factors or the combined action of the factors.
At present, the main methods for preventing and treating the prostatic hyperplasia diseases mainly carry out medicament treatment besides physical treatment and surgical treatment, and western medicaments such as antibiotics are mainly used for preventing and treating the prostatic hyperplasia diseases in the medicaments, so that the recurrence rate is high and certain side effects are caused.
It has been found that some plants contain active ingredients that have some effect on prostate disorders. Research on Chenzhi strong team of urology scientific research institute of the first subsidiary hospital of Guangxi medical university finds that curcumin has an induction effect on apoptosis of human prostatic hyperplasia interstitial cells, and the turmeric extract is proved to have a good effect of treating benign prostatic hyperplasia. On the other hand, the research of K.F. KLIPPEL et al at the university of Dreuston's science and technology shows that the beta-sitosterol (mainly from vegetable oil) also has the effect of improving the prostatic hyperplasia. However, there is no relevant literature or published technology to conduct intensive research and screen edible ingredients which can be matched with turmeric and have synergistic effect, and there is no relevant published technology or technical hint that turmeric and phytosterol can be compounded to improve the effect of prostate hyperplasia.
Disclosure of Invention
Based on the shortcomings of the prior art, the invention aims to provide a composition for inhibiting prostatic hyperplasia.
In order to achieve the purpose, the invention adopts the technical scheme that:
a composition for inhibiting prostatic hyperplasia comprises the following components: turmeric and phytosterol esters.
The composition for inhibiting prostatic hyperplasia comprises dried rhizome extract of Curcuma rhizome (Curcuma longa L.) belonging to Curcuma of Zingiberaceae, and curcumin as main chemical component. Curcuma rhizome has anti-tumor, antioxidant, liver protecting, blood sugar lowering, antiinflammatory, antibacterial, and antiviral effects. Curcumin compounds in Curcuma rhizome have effects of reducing inflammatory cytokine in prostate tissue, inhibiting prostate cancer cell proliferation, inhibiting 15-lipoxygenase (15-LOX), and inducing apoptosis of hormone-dependent prostate cancer cell LNCaP and hormone-independent prostate cancer cell PC 3. Meanwhile, curcumin can inhibit the proliferation of prostate interstitial cells and induce the prostate interstitial cells to generate apoptosis; the phytosterol ester is mainly derived from vegetable oil such as soybean oil, rapeseed oil, corn oil, sunflower seed oil, tall oil and the like, is generally prepared by extracting phytosterol from the vegetable oil and performing esterification reaction on the phytosterol and fatty acid, the active ingredient of the phytosterol ester is the phytosterol, the main sterols comprise beta-sitosterol, stigmasterol, campesterol and the like, the phytosterol ester has the effects of reducing cholesterol, preventing cardiovascular diseases, resisting inflammation, resisting cancer and the like, and the contained sterols have similar structures with dihydrotestosterone and can compete with the dihydrotestosterone to inhibit the combination of the dihydrotestosterone and a receptor so as to improve the prostatic hyperplasia.
The composition for inhibiting the prostatic hyperplasia is prepared by matching turmeric and phytosterol ester, wherein the turmeric can inhibit inflammatory factors, can inhibit the proliferation of prostatic interstitial cells and induce the apoptosis of the prostatic interstitial cells, and can obviously reduce the wet weight of the prostate and reduce the prostate index; the phytosterol ester has similar structure to dihydrotestosterone, and can compete with dihydrotestosterone to inhibit the binding of dihydrotestosterone to receptor, thereby improving prostatic hyperplasia. The two components are compounded and coordinated with each other to improve the prostatic hyperplasia and have beneficial effect on preventing the prostatic diseases. In addition, the above two components are common food materials or food additives, and the composition has high safety.
Preferably, the composition for inhibiting the prostatic hyperplasia consists of the following components in parts by weight: 12.5-25 parts of turmeric and 12.5-100 parts of phytosterol ester. Under the condition of the components in parts by weight, the inhibition efficiency of the collocation of the components on the prostatic hyperplasia is obviously improved. The composition prepared at this specific ratio has the highest efficiency of inhibiting prostatic hyperplasia.
The invention also aims to provide a preparation method of the composition for inhibiting the prostatic hyperplasia.
The preparation method of the composition for inhibiting the prostatic hyperplasia comprises the step of uniformly mixing turmeric and phytosterol ester to obtain the composition for inhibiting the prostatic hyperplasia.
The preparation method of the composition for inhibiting the prostatic hyperplasia, which is provided by the invention, has simple preparation process and can be industrially produced in a large scale.
Meanwhile, the two components in the composition can be prepared and extracted according to actual conditions, can be directly purchased from the market, and can be replaced by raw materials, semi-finished products or added finished products with the same components without influencing the efficacy of the prepared product: the Curcuma rhizome can be prepared from Curcuma rhizome; the phytosterol ester can be replaced by vegetable oil containing phytosterol or phytosterol.
The invention also aims to provide the application of the composition for inhibiting the prostatic hyperplasia in the preparation of products for inhibiting the prostatic hyperplasia. The composition for inhibiting the prostatic hyperplasia has stable performance, can be processed into various dosage forms, and is suitable for processing and preparing products in various forms.
More preferably, the product for inhibiting prostatic hyperplasia comprises food, health product or medicine.
Preferably, the product for inhibiting the prostatic hyperplasia further comprises auxiliary materials, wherein the auxiliary materials comprise a flavoring agent, a thickening agent, a disintegrating agent and a filling agent. On the premise of not influencing the main components for inhibiting the prostatic hyperplasia, the necessary auxiliary materials are added in the product to further enhance and provide the taste, the storage stability, the effect and the like of the product, and the person skilled in the art can select the common content according to the conventional standard.
Preferably, the dosage form of the product for inhibiting prostatic hyperplasia comprises solid beverage, granules, capsules or tablets. On the premise of not influencing the component structure and the component stability of the composition, the dosage form of the product can be adjusted according to the actual requirement.
The composition for inhibiting the prostatic hyperplasia is prepared by compounding turmeric and phytosterol ester, wherein curcumin compounds in the turmeric have the effects of reducing inflammatory cytokines in prostatic tissues and inhibiting the proliferation of prostatic cancer cells, have a good inhibiting effect on 15-lipoxygenase (15-LOX), and can induce the apoptosis of hormone prostatic cancer cells. Meanwhile, curcumin can inhibit the proliferation of prostate interstitial cells and induce the prostate interstitial cells to generate apoptosis; the phytosterol ester has the effects of reducing cholesterol, preventing cardiovascular diseases, resisting inflammation, resisting cancer and the like, contains sterol and dihydrotestosterone which have similar structures, can compete with the dihydrotestosterone, inhibits the combination of the dihydrotestosterone and a receptor, and further can improve the hyperplasia of prostate. The synergistic effect between the two can effectively inhibit the hyperplasia of prostate. In addition, the composition for inhibiting the prostatic hyperplasia has high safety and no toxic or side effect. The invention also provides a preparation method of the composition for inhibiting the prostatic hyperplasia, and the preparation method has simple preparation process and can be used for industrial mass production. The invention also provides application of the composition for inhibiting the prostatic hyperplasia in preparation of products for inhibiting the prostatic hyperplasia.
Detailed Description
Unless otherwise specified, the raw materials used in the examples of the present invention and comparative examples were commercially available, and the production equipment used was a commercially available common model. The turmeric Ar juna Natural Extracts Ltd in the examples and comparative examples of the present invention is provided by production; the phytosterol ester is a product produced by basf corporation, and the phytosterol ester content is about 97%.
For better illustrating the objects, technical solutions and advantages of the present invention, the present invention will be further described with reference to specific examples, which are intended to be understood in detail, but not intended to limit the present invention.
Example 1
One embodiment of the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 12.5 parts of turmeric and 100 parts of phytosterol ester.
The preparation method of the composition for inhibiting prostatic hyperplasia comprises the following steps: sieving turmeric and phytosterol ester, weighing according to the weight parts, uniformly mixing and subpackaging to obtain the product for inhibiting the prostatic hyperplasia.
Example 2
One embodiment of the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 12.5 parts of turmeric and 50 parts of phytosterol ester.
The preparation of the composition for inhibiting prostatic hyperplasia described in this example is the same as in example 1.
Example 3
One embodiment of the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 12.5 parts of turmeric and 25 parts of phytosterol ester.
The preparation of the composition for inhibiting prostatic hyperplasia described in this example is the same as in example 1.
Example 4
One embodiment of the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 12.5 parts of turmeric and 12.5 parts of phytosterol ester.
The preparation of the composition for inhibiting prostatic hyperplasia described in this example is the same as in example 1.
Example 5
One embodiment of the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 25 parts of turmeric and 12.5 parts of phytosterol ester.
The preparation of the composition for inhibiting prostatic hyperplasia described in this example is the same as in example 1.
Example 6
One embodiment of the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 15 parts of turmeric and 90 parts of phytosterol ester; the composition is used for preparing a product for inhibiting the hyperplasia of prostate, and the product also comprises: and 70 parts of a flavoring agent.
The preparation method of the product for inhibiting the prostatic hyperplasia comprises the following steps: weighing the components according to the corresponding weight parts, sieving the components, feeding the components into a mixer, and uniformly mixing the components to obtain the product for inhibiting the prostatic hyperplasia.
Example 7
One embodiment of the composition for inhibiting the prostatic hyperplasia comprises the following components in parts by weight: 20 parts of turmeric and 85 parts of phytosterol ester; the composition is used for preparing a product for inhibiting the hyperplasia of prostate, and the product also comprises: 30 parts of flavoring agent, 40 parts of maltodextrin, 50 parts of microcrystalline cellulose, 305 parts of povidone K, 2 parts of silicon dioxide and 3 parts of magnesium stearate.
The preparation method of the product for inhibiting the prostatic hyperplasia comprises the following steps: sieving the components, weighing the components in parts by weight, feeding the components into a mixer, uniformly mixing, granulating or not granulating, tabletting and bottling to obtain the product for inhibiting the prostatic hyperplasia.
Comparative example 1
The comparative example differs from example 1 only in that the composition of the comparative example has the following components: 25 parts of turmeric.
Comparative example 2
The comparative example differs from example 1 only in that the composition of the comparative example has the following components: 12.5 parts of turmeric.
Comparative example 3
The comparative example differs from example 1 only in that the composition of the comparative example has the following components: 100 parts of phytosterol ester.
Comparative example 4
The comparative example differs from example 1 only in that the composition of the comparative example has the following components: 50 parts of phytosterol ester.
Comparative example 5
The comparative example differs from example 1 only in that the composition of the comparative example has the following components: and 25 parts of phytosterol ester.
Comparative example 6
The comparative example differs from example 1 only in that the composition of the comparative example has the following components: 12.5 parts of phytosterol ester.
In order to verify the influence of the composition for inhibiting the prostatic hyperplasia, prepared in the examples 1-5 and the comparative examples 1-6, on the prostatic hyperplasia cells, the composition products are used for the BPH-1 cell culture test.
The test uses human benign prostatic hyperplasia BPH-1 cells derived from prostatic epithelial tissue of a patient with prostatic hyperplasia;
the cell suspension and the added reagent used in the test are: 1640 culture solution, trypsin, PBS buffer solution, tetramethyl azozolium (MTT) and dimethyl sulfoxide (DMSO);
the experimental instruments needed to be used in the test are as follows: the device comprises a 96-pore plate, a biological safety cabinet, a carbon dioxide incubator, an enzyme-labeling instrument and an inverted microscope;
the test comprises the following specific steps: digesting human benign prostatic hyperplasia cell BPH-1, preparing single cell suspension with culture solution, and adjusting cell density to 1x104Inoculating each cell/well in 96-well plate with volume of 200 μ L, placing at 37 deg.C and 5% CO2After incubation for 24h in an incubator in a culture environment, the cells are adhered to the wall, and then the cells are treated for 48h by using test groups with different concentration ratios, wherein the dosages of the components of the test groups are shown in table 1. After treatment, the culture medium in the culture wells was removed, 20. mu.L of MTT solution (500mg MTT in 100ml PBS) was added to each well, incubation was continued for 4h, the culture was terminated, and the culture supernatant in the wells was carefully aspirated, which was necessary for suspension of the cellsAfter centrifugation, the culture supernatant in the wells was aspirated. Add 150. mu.L DMSO solution into each well, shake for 10min to fully melt the crystals. The absorbance of each well was measured on a microplate reader at 490nm, and the results are shown in table 2, where% cell proliferation ÷ component absorbance value ÷ blank control absorbance value × 100%.
TABLE 1
TABLE 2
Note: # is relative to the blank group and is relative to the turmeric group at equivalent concentration; @ is relative to the same concentration phytosterol ester group; @, #######, or @ @ indicates that p < 0.001; a, # # or @ @ indicates p <0.01, extremely significant; significant, # or @ indicates p < 0.05; the smaller the p-value, the more significant the difference.
As can be seen from table 2, the phytosterol esters corresponding to comparative examples 3-6 do not show the inhibition effect on the BPH-1 of the prostate hyperplasia cells at the low concentration of 12.5 μ g/mL, and show the inhibition effect when the concentration is doubled, but the inhibition effect is not good when the concentration is doubled, which indicates that the single phytosterol ester has the function of improving the prostate hyperplasia at a certain concentration, but the effect is limited; according to comparative examples 1-2, the turmeric has the effect of obviously improving the prostatic hyperplasia, the effect is more obvious along with the increase of the concentration, but the effect of inhibiting the prostatic hyperplasia is preferably less than 45%; compared with the turmeric or phytosterol ester comparative example group at the same concentration, the compositions for inhibiting the prostatic hyperplasia prepared in the examples 1-5 have significant difference or extremely significant difference in inhibiting the prostatic hyperplasia, which shows that the hyperplasia inhibition effect is superior to that of the turmeric or phytosterol ester at the same concentration, wherein the cell proliferation rate of the composition for inhibiting the prostatic hyperplasia in the example 1 is only 25.12% after the composition for inhibiting the prostatic hyperplasia treats the prostatic hyperplasia cells BPH-1, and the hyperplasia inhibition effect can reach 74.88%. Therefore, the turmeric and the phytosterol ester are compounded to have a synergistic effect, and the prepared composition for inhibiting the prostatic hyperplasia has an obvious effect of inhibiting the prostatic cell hyperplasia.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (6)
1. A composition for inhibiting prostatic hyperplasia, which comprises the following components: turmeric and phytosterol esters.
2. The composition for inhibiting prostatic hyperplasia according to claim 1, which consists of the following components in parts by weight: 12.5-25 parts of turmeric and 12.5-100 parts of phytosterol ester.
3. The method of preparing a composition for inhibiting prostatic hyperplasia according to any one of claims 1 to 2, wherein the method comprises: the composition for inhibiting prostatic hyperplasia can be obtained by mixing Curcuma rhizome and phytosterol ester uniformly.
4. Use of the composition for inhibiting prostatic hyperplasia according to any one of claims 1-2 in the preparation of a product for inhibiting prostatic hyperplasia.
5. The use of the composition for inhibiting prostatic hyperplasia according to claim 4 in the preparation of a product for inhibiting prostatic hyperplasia, wherein the components of the product for inhibiting prostatic hyperplasia further comprise adjuvants, and the adjuvants comprise a flavoring agent, a thickening agent, a disintegrating agent and a filler.
6. The use of the composition for inhibiting prostatic hyperplasia according to claim 5 in the preparation of a product for inhibiting prostatic hyperplasia, wherein the dosage form of the product for inhibiting prostatic hyperplasia comprises solid beverage, granules, capsules or tablets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011599001.4A CN112715938A (en) | 2020-12-28 | 2020-12-28 | Composition for inhibiting prostatic hyperplasia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011599001.4A CN112715938A (en) | 2020-12-28 | 2020-12-28 | Composition for inhibiting prostatic hyperplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112715938A true CN112715938A (en) | 2021-04-30 |
Family
ID=75611518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011599001.4A Withdrawn CN112715938A (en) | 2020-12-28 | 2020-12-28 | Composition for inhibiting prostatic hyperplasia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112715938A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1720030A (en) * | 2002-12-06 | 2006-01-11 | 帝斯曼知识产权资产管理有限公司 | The new purposes of lycopene |
| CN103054025A (en) * | 2013-01-04 | 2013-04-24 | 浙江大学 | Health-care food composition for preventing and treating prostate disease |
-
2020
- 2020-12-28 CN CN202011599001.4A patent/CN112715938A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1720030A (en) * | 2002-12-06 | 2006-01-11 | 帝斯曼知识产权资产管理有限公司 | The new purposes of lycopene |
| CN103054025A (en) * | 2013-01-04 | 2013-04-24 | 浙江大学 | Health-care food composition for preventing and treating prostate disease |
Non-Patent Citations (1)
| Title |
|---|
| 武谦虎: "《常用治疗肝病中药》", 31 December 2014, 中国医药科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shen et al. | Policosanol: Extraction and biological functions | |
| Cheurfa et al. | Hypocholesterolaemic and antioxidant properties of Olea europaea L. leaves from Chlef province, Algeria using in vitro, in vivo and in silico approaches | |
| CN1803010A (en) | Black edible fungus health food and its preparation method | |
| Yang et al. | Determination of active compounds in raspberry leaf extracts and the effects of extract intake on mice | |
| Wu et al. | Hypoglycemic effect of okra aqueous extract on streptozotocin-induced diabetic rats | |
| He et al. | New understanding of Angelica sinensis polysaccharide improving fatty liver: The dual inhibition of lipid synthesis and CD36-mediated lipid uptake and the regulation of alcohol metabolism | |
| Tan et al. | Anti-inflammatory and intestinal microbiota modulation properties of high hydrostatic pressure treated cyanidin-3-glucoside and blueberry pectin complexes on dextran sodium sulfate-induced ulcerative colitis mice | |
| CN108497498A (en) | A kind of functional food of relieving alcoholism and protecting liver and preparation method thereof | |
| CN114042146B (en) | Bovine bone peptide composition and application thereof in preparation of medicines for regulating intestinal flora and preventing and treating osteoporosis | |
| CN112603982A (en) | Composition for inhibiting prostatic hyperplasia | |
| CN112715938A (en) | Composition for inhibiting prostatic hyperplasia | |
| CN109512851B (en) | Preparation method of medical antibacterial midwifery gel | |
| CN102228666B (en) | Composition prepared from pine pollen and curcuma, preparation method thereof, and application of composition in preparing medicament for treating inflammatory bowel disease | |
| CN105796764B (en) | Preparation method and application of negundo chastetree fruit total lignans | |
| CN112656915A (en) | Composition for inhibiting prostatic hyperplasia | |
| WO2021174801A1 (en) | Method for preparing antrodia cinnamomea water-insoluble dietary fibers | |
| CN110314186B (en) | Traditional Chinese medicine composition for preventing and treating enteritis of aquatic animals and preparation method thereof | |
| CN113908198A (en) | A composition for preventing and treating prostate diseases, and its preparation method | |
| CN112569337A (en) | Composition for inhibiting prostatic hyperplasia | |
| CN113144134A (en) | Pharmaceutical composition for inhibiting prostate cancer and application thereof | |
| EP2680924B1 (en) | A novel herbal composition for the treatment of kidney stone and other urinary tract disorders | |
| CN113577220A (en) | Medicinal composition for inhibiting prostate cancer and application thereof | |
| CN112656913A (en) | Composition for inhibiting prostatic hyperplasia and preparation method and application thereof | |
| JP7289884B2 (en) | Anticancer drug composition | |
| CN112807403A (en) | Application of composition in preparation of product for inhibiting prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210430 |
|
| WW01 | Invention patent application withdrawn after publication |